Applied Therapeutics, a clinical-stage biopharmaceutical company, is under heightened scrutiny following the issuance of a November 2024 Warning Letter1 from the US Food and Drug Administration (FDA) on the heels of a routine preapproval bioresearch monitoring (BIMO) inspection.2 FDA’s BIMO program is designed to ensure the integrity of data submitted to FDA, and to protect the rights, safety and welfare of research participants.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Elizabeth Caruso
Certain Stem Cell Products Require FDA Premarket Approval | JD Supra
On September 27, 2024, in USA v.
FDA Finalizes Guidance on Use of Part 11 Electronic Systems, Records and Signatures in Clinical Investigations | JD Supra
On October 1, 2024, the US Food and Drug Administration (FDA) finalized its guidance on the use of electronic records in clinical investigations of drugs, devices, biologics, foods, tobacco products and new animal drugs. The guidance is intended to assist a wide range of stakeholders – including sponsors, clinical investigators, institutional review boards (IRBs) and contract research organizations (CROs) – on good clinical practice compliance.
FDA Finalizes Guidance on Use of Part 11 Electronic Systems, Records and Signatures in Clinical Investigations
On October 1, 2024, the US Food and Drug Administration (FDA) finalized its guidance on the use of electronic records in clinical investigations of drugs, devices, biologics, foods, tobacco products and new animal drugs. The guidance is intended to assist a wide range of stakeholders – including sponsors, clinical investigators, institutional review boards (IRBs) and contract research organizations (CROs) – on good clinical practice compliance.
FDA Targets April 2024 For Laboratory Developed Test (LDT) Final Rule
On December 6, 2023, the Office of Information and Regulatory Affairs ("OIRA") released the Fall 2023 Unified Agenda of Regulatory and Deregulatory Actions (the "Agenda"), a semiannual compilation of information regarding regulations under development by federal agencies.
FDA Targets April 2024 for Laboratory Developed Test (LDT) Final Rule | JD Supra
On December 6, 2023, the Office of Information and Regulatory Affairs (“OIRA”) released the Fall 2023 Unified Agenda of Regulatory and Deregulatory Actions (the “Agenda”), a semiannual compilation of information regarding regulations under development by federal agencies.
Newly Launched: Goodwin's Laboratory Developed Tests Resource Page
Our Life Sciences Regulatory & Compliance team has launched a new resource page, keeping you up-to-date on the latest regulatory developments affecting laboratory developed tests (LDTs). Our dedicated LDT page provides foundational materials, legislative and regulatory history, and updates and analyses regarding initiatives to increase oversight over LDTs, including FDA's LDT Proposed Rule (October 2020).
Newly Launched: Goodwin’s Laboratory Developed Tests Resource Page
Our Life Sciences Regulatory & Compliance team has launched a new resource page, keeping you up-to-date on the latest regulatory developments affecting laboratory developed tests (LDTs). Our dedicated LDT page provides foundational materials, legislative and regulatory history, and updates and analyses regarding initiatives to increase oversight over LDTs, including FDA’s LDT Proposed Rule (October 2020).
FDA's Proposed Rule For Oversight Of Laboratory Developed Tests: Part II: FDA's Proposed Phaseout Policy – Key Considerations & Open Questions - Healthcare - United States
Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms.
FDA’s Proposed Rule for Oversight of Laboratory Developed Tests: Part I: Underpinnings of FDA’s Proposed Rule
On October 3, 2023, the U.S. Food and Drug Administration (FDA) published its widely anticipated proposed rule on the regulation of laboratory developed tests (LDTs).
FDA’s Proposed Rule for Oversight of Laboratory Developed Tests: Part I: Underpinnings of FDA’s Proposed Rule | JD Supra
On October 3, 2023, the U.S. Food and Drug Administration (FDA) published its widely anticipated proposed rule on the regulation of laboratory developed tests (LDTs).
FDA's Proposed Rule For Oversight Of Laboratory Developed Tests: Part I: Underpinnings Of FDA's Proposed Rule
On October 3, 2023, the U.S. Food and Drug Administration (FDA) published its widely anticipated proposed rule on the regulation of laboratory developed tests (LDTs).
Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions | JD Supra
On September 6, 2023, the US Food and Drug Administration (FDA) released a trio of draft guidances in its efforts to “strengthen and modernize” the 510(k) Program and provide for more “predictability, consistency, and transparency” for the 510(k) premarket review process.
Modernizing The FDA's 510(k) Program For Medical Devices: Selection Of Predicate Devices And Use Of Clinical Data In 510(k) Submissions
On September 6, 2023, the US Food and Drug Administration (FDA) released a trio of draft guidances in its efforts to "strengthen and modernize" the 510(k) Program and provide for more "predictability, consistency, and transparency" for the 510(k) premarket review process.
Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions
On September 6, 2023, the US Food and Drug Administration (FDA) released a trio of draft guidances in its efforts to “strengthen and modernize” the 510(k) Program and provide for more “predictability, consistency, and transparency” for the 510(k) premarket review process.
Common FDA Bioresearch Monitoring Violations: Updates From FY 2022 To Now - Life Sciences, Biotechnology & Nanotechnology - United States
The Bioresearch Monitoring (BIMO) Program, operated by the U.S. Food and Drug Administration (FDA), conducts on-site inspections and data audits in order to effectively monitor the compliance of all FDA-regulated research. As a follow up to our June 2022 post, we highlight the most common violations identified in Fiscal Year (FY) 2022, in addition to those observed thus far in FY 2023. BIMO conducted 766 inspections in FY 2022.
Common FDA Bioresearch Monitoring Violations: Updates from FY 2022 to Now | JD Supra
The Bioresearch Monitoring (BIMO) Program, operated by the U.S. Food and Drug Administration (FDA), conducts on-site inspections and data audits in order to effectively monitor the compliance of all FDA-regulated research. As a follow up to our June 2022 post, we highlight the most common violations identified in Fiscal Year (FY) 2022, in addition to those observed thus far in FY 2023. BIMO conducted 766 inspections in FY 2022.
Common FDA Bioresearch Monitoring Violations: Updates from FY 2022 to Now
The Bioresearch Monitoring (BIMO) Program, operated by the U.S. Food and Drug Administration (FDA), conducts on-site inspections and data audits in order to effectively monitor the compliance of all FDA-regulated research. As a follow up to our June 2022 post, we highlight the most common violations identified in Fiscal Year (FY) 2022, in addition to those observed thus far in FY 2023. BIMO conducted 766 inspections in FY 2022.
The ABCs of DCTs: New FDA Guidance Provides Recommendations for the Conduct of Decentralized Clinical Trials | JD Supra
On May 2, 2023, the U.S. Food and Drug Administration (“FDA”) published draft guidance titled “Decentralized Clinical Trials for Drugs, Biological Products, and Devices” (the “Draft Guidance”).
The ABCs of DCTs: New FDA Guidance Provides Recommendations for the Conduct of Decentralized Clinical Trials
On May 2, 2023, the U.S. Food and Drug Administration (“FDA”) published draft guidance titled “Decentralized Clinical Trials for Drugs, Biological Products, and Devices” (the “Draft Guidance”).
FDA’s Final Q&A Guidance on Risk-Based Monitoring of Clinical Trials Provides Additional Recommendations for Sponsors | JD Supra
The U.S. Food and Drug Administration (FDA) recently finalized its guidance, “A Risk-Based Approach to Monitoring of Clinical Investigations” (the “2023 RBM Guidance”) which follows up on the Agency’s March 2019 draft guidance (the “Draft Guidance”) of the same name and expands on (but does not supersede) the FDA’s August 2013 guidance, “Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring” (the “2013 RBM Guidance”), with new recommendations summarized below to aid...
Viewpoint: Vote yes to save Maine - Mount Desert Islander
By Elizabeth Caruso As an intervenor in the three state permitting proceedings, I am personally acquainted with the expert testimonies and evidence submitted for the NECEC project. Testifying at the Legislature, I witnessed a foreign-corporate army of lobbyists hammering upon our citizen legislators. I am writing to conscientious, knowledgeable Maine citizens who are concerned about Maine’s economy, climate future, a green pathway with its associated implications.
Commentary: Maine towns should have a say in for-profit transmission projects
Opinion increase font size L.D. 1383 – requiring local approval for eminent domain in proposals like the CMP corridor – would protect towns and property owners.
Commentary: Maine towns should have a say in for-profit transmission projects
Opinion increase font size L.D. 1383 – requiring local approval for eminent domain in proposals like the CMP corridor – would protect towns and property owners.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Elizabeth
Contact Elizabeth, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack